Latest Migraine Stories
MORRISTOWN, N.J., Sept. 1, 2011 /PRNewswire/ -- A new meta-analysis published this week in Drugs in R&D(1), reaffirms the safety profile of aspirin for short-term treatment of mild to moderate pain, and aches and fever due to colds when used as directed. The analysis of 67 clinical trials of aspirin for pain relief/fever reduction - the largest conducted to date - encompassed more than 20 years of research and involved mostly single-dose treatment of acute pain. Patient-reported data...
Migraine treatment known as the StimPath procedure was featured on Top Docs as a treatment to help individuals who suffer from debilitating headache pain. Dallas, TX (PRWEB) August 13, 2011 Ascendant Neuro announced that the StimPath procedure, an innovative migraine treatment for people who suffer from debilitating headache pain, was featured on the July 31 edition of Top Docs of DFW, the popular Sunday morning program on KDAF-TV, Channel 33. "What we've developed is a procedure using...
MOUNTAIN VIEW, Calif., Aug. 11, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent No. 7,994,197, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile." The patent, which expires in 2028, results from the Company's discovery that dihydroergotamine (DHE) can be administered to achieve pharmacokinetic...
NEW YORK, Aug. 8, 2011 /PRNewswire/ -- Global Health Ventures Inc. (OTCBB: GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery announced today that their August 4th RetailInvestorConferences.com presentation by Dr. Hassan Salari PhD, Chairman and CEO, is available for on-demand viewing. LINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button. Their presentation will be available 24/7 for 90 days. Investors may download...
MOUNTAIN VIEW, Calif., Aug. 4, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2011. The net loss for the three months ended June 30, 2011 was $8.6 million compared to $12.5 million during the same period in 2010. The net income for the first six months of 2011 was $9.0 million compared to a net loss of $26.5 million during the same period in 2010. Net income for the first six months of 2011 was impacted...
MOUNTAIN VIEW, Calif., Aug. 2, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that its New Drug Application (NDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA), with a goal date of March 26, 2012 under the Prescription Drug User Fee Act (PDUFA). In accordance with the Company's collaboration agreement with Allergan, Inc., the FDA's...
NEW YORK, Aug. 1, 2011 /PRNewswire/ -- Global Health Ventures Inc. (OTCBB: GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery announced today that Dr. Hassan Salari PhD, Chairman and CEO will be presenting at RetailInvestorConferences.com. DATE: August 4, 2011TIME: 7:00pm EDTLINK: www.retailinvestorconferences.com>Click the red "register/ watch event now" button. This will be a live, interactive online event where investors are invited to ask the company...
YONKERS, N.Y., July 21, 2011 /PRNewswire-USNewswire/ -- A new reader survey published in the September issue of Consumer Reports and available online at www.ConsumerReportshealth.org finds that three of four adults use some form of alternative therapy for general health. Readers rated prescription drugs as helping the most for the majority of 12 health problems, but chiropractic, deep-tissue massage, and yoga, dominated the lists of helpful alternative treatments for discomfort from...
REHOVOT, Israel, July 20, 2011 /PRNewswire/ -- D-Pharm Ltd., (TASE: DPRM) announced today that the Data and Safety Monitoring Board (DSMB) for the Membrane Activated Chelator Stroke Intervention (MACSI) study recommended that the study continue as planned. The DSMB conducted a comprehensive unblinded review of safety data from the first 200 patients that completed follow-up in the MACSI study, as well as a review of all serious adverse event (SAE) data from previous DP-b99...
Treating chronic migraines with behavioral approaches - such as relaxation training, hypnosis and biofeedback - can make financial sense compared to prescription-drug treatment, especially after a year or more, a new study found.Longtime behavioral therapy researcher and practitioner Dr. Donald Penzien, University of Mississippi Medical Center professor of psychiatry, coauthored the study. He said the costs of prescription prophylactic drugs - the kind chronic migraine sufferers take every...
Latest Migraine Reference Libraries
Heat therapy is a treatment in the medical field to relieve pain and improve over health. It can be a therapy used only once, repeatedly in rehabilitation sessions, or as part of an after-care routine in sports medicine. It can be delivered in many forms with success in all. How the Heat Helps As heat is introduced to the area, the temperature will increase beginning from the outer layer and moving deeper into the tissues. After the change in temperature, the blood vessels in the area of...
The Corrugator Supercilii is a small, narrow, pyramidal muscle found on the medial end of the eyebrow, beneath the Frontalis and just above the orbicularis oculi. It arises from the medial end of the superciliary arch, and its fibers pass upward and lateralward, between the palpebral and orbital portions of the Orbicularis oculi, and are inserted into the deep surface of the skin, above the middle of the orbital arch. This muscle draws the eyebrow downward and medialward and produce the...
